🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Fortis Healthcare Limited FORTIS NIFTY_MIDNSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.fortishealthcare.com
Company Profile ↓
₹905.00
-2.76% 1Y
Mkt Cap₹68,323.71 Cr
P/E65.58
P/B7.29
Div. Yield0.11%
52W High₹1,096.74
52W Low₹787.91
Book Value₹131.07
EPS (TTM)₹13.80

Company Overview

Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company services in the areas of cardiac science, nephrology, diabetology/endocrinology, foetal medicine, infectious diseases, mental health and behavioral science, oncology, orthopedics, physiotherapy and rehabilitation, rheumatology, urology, nuclear medicine, critical care, emergency and trauma, general surgery, internal medicine, neurointerventional radiology, obstetrics and gynaecology, pediatrics, pediatrics, vascular surgery, and support facilities. It also provides services in the areas of infertility medicine, dental science, endocrine surgery, geriatric medicine, liver transplant and hepatobiliary sciences, neurology, ophthalmology, pain and palliative medicine, pulmonology, thoracic surgery, gastroenterology sciences, dermatology, ENT, haematology, medical generics, neurology, organ transplant, radiology, and transfusion medicines. In addition, the company offers various spectrum integrated healthcare services ranging from clinics to quaternary care facilities and a range of ancillary services, as well as secondary, and tertiary care services. The company's healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 21.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 13.3% CAGR over the past five years.

Healthy Margins

Operating margin of 17.8% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.35.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹9,048.08 Cr (+17.1% YoY); net profit ₹1,041.77 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +17.1%, earnings +34.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.3%, profit CAGR 21.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.35%
1 Year:17.14%

Compounded Profit Growth

5 Years:20.95%
1 Year:34.56%

Stock Price Performance

1 Year:-2.76%
6 Months:+1.50%
3 Months:-8.47%
1 Month:-1.63%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 38% of range
₹787.91 ₹1,096.74
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)42.79 · Neutral
Price Performance
1M-1.63%
3M-8.47%
6M+1.50%
1Y-2.76%
Valuation vs Sector

P/E of 65.58 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 13.3% over 5 years.
  • Profit CAGR of 21.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 65.6.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
65.58
Industry PE
41.64
Forward P/E
38.92
PEG Ratio
0.42
Book Value
₹131.07
Price to Book
7.29
P/S
7.59
EV/EBITDA
34.57
Dividend Yield
0.11%

Growth (CAGR)

Revenue 5Y
13.35%
Profit 5Y
20.95%
Revenue (YoY)
17.14%
Earnings (YoY)
34.56%

Profitability & Returns

ROCE
11.90%
ROE
10.53%
ROA
6.52%
Profit Margin
11.51%
Op Margin
17.84%
Gross Margin
61.06%
EPS (Latest Qtr)
₹3.53
EPS (TTM)
₹13.80

Balance Sheet & Liquidity

Debt/Equity
0.35
Quick Ratio
0.80
Current Ratio
0.86
Debt
₹3,472.58 Cr
Total Assets
₹15,966.23 Cr
Current Assets
₹1,819.42 Cr
Working Capital
₹-295.58 Cr

Ownership

Promoter Holding
35.19%
Chg in Prom Hold
-
FII / Inst Holding
50.91%
Chg in FII Hold
-0.11%

Financial Snapshot

Enterprise Value
₹68,323.71 Cr
Total Revenue (TTM)
₹9,048.08 Cr
EBITDA
₹2,097.86 Cr
Free Cash Flow
₹656.00 Cr
Operating Cash Flow
₹1,601.45 Cr
Shares Outstanding
₹75.50 Cr
Gross Margin
61.06%
Payout Ratio
7.25%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FORTIS Fortis Healthcare Limited NIFTY_MIDNSEPHARMA 905.00 65.58 ₹68,323.71 Cr 0.11% 11.90% 10.53% 13.35% 20.95%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 1,643.00 Cr1,657.00 Cr1,770.00 Cr1,680.00 Cr1,786.00 Cr1,859.00 Cr---2,166.72 Cr2,331.44 Cr2,265.01 Cr2,364.67 Cr2,545.03 Cr
Cost of Revenue ---------975.20 Cr1,033.48 Cr1,009.68 Cr1,020.15 Cr1,124.60 Cr
Gross Profit ---------1,191.52 Cr1,297.96 Cr1,255.33 Cr1,344.52 Cr1,420.43 Cr
Operating Expenses 1,372.00 Cr1,386.00 Cr1,440.00 Cr1,396.00 Cr1,405.00 Cr1,516.00 Cr---802.33 Cr847.47 Cr869.82 Cr934.16 Cr1,005.19 Cr
Operating Income 189.00 Cr193.00 Cr246.00 Cr197.00 Cr289.00 Cr252.00 Cr---389.19 Cr450.49 Cr385.51 Cr410.36 Cr415.24 Cr
EBITDA 271.00 Cr272.00 Cr330.00 Cr284.00 Cr381.00 Cr343.00 Cr---521.62 Cr606.12 Cr471.56 Cr530.45 Cr565.50 Cr
Interest Expense 32.00 Cr31.00 Cr32.00 Cr33.00 Cr35.00 Cr35.00 Cr---69.57 Cr74.88 Cr85.74 Cr84.28 Cr80.44 Cr
Pretax Income 183.00 Cr171.00 Cr233.00 Cr183.00 Cr271.00 Cr230.00 Cr---350.57 Cr425.40 Cr265.68 Cr324.20 Cr363.18 Cr
Tax Provision 45.75 Cr46.17 Cr48.93 Cr49.41 Cr67.75 Cr55.20 Cr---83.79 Cr96.58 Cr68.28 Cr53.01 Cr90.38 Cr
Net Income 138.00 Cr124.00 Cr184.00 Cr134.00 Cr203.00 Cr174.00 Cr---260.28 Cr321.92 Cr193.73 Cr265.85 Cr266.39 Cr
Diluted EPS 1.761.482.301.782.372.20---3.454.262.573.523.53

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 3,966.00 Cr4,199.00 Cr4,574.00 Cr4,561.00 Cr4,469.00 Cr4,632.00 Cr4,030.00 Cr-6,213.15 Cr6,835.09 Cr7,723.89 Cr9,048.08 Cr
Cost of Revenue --------3,994.58 Cr4,387.99 Cr3,115.68 Cr3,523.42 Cr
Gross Profit --------2,218.58 Cr2,447.10 Cr4,608.21 Cr5,524.66 Cr
Operating Expenses 3,857.00 Cr4,106.00 Cr4,220.00 Cr4,287.00 Cr4,238.00 Cr4,022.00 Cr3,626.00 Cr-1,448.34 Cr1,534.82 Cr3,415.49 Cr3,910.27 Cr
Operating Income -126.00 Cr-133.00 Cr132.00 Cr35.00 Cr-2.00 Cr318.00 Cr113.00 Cr-770.24 Cr912.28 Cr1,192.72 Cr1,614.39 Cr
EBITDA 109.00 Cr92.00 Cr354.00 Cr274.00 Cr231.00 Cr610.00 Cr404.00 Cr-1,237.80 Cr1,308.51 Cr1,547.49 Cr2,097.86 Cr
Interest Expense 152.00 Cr133.00 Cr229.00 Cr258.00 Cr337.00 Cr205.00 Cr166.00 Cr-108.39 Cr108.05 Cr154.83 Cr282.58 Cr
Pretax Income -185.00 Cr34.00 Cr552.00 Cr-912.00 Cr-110.00 Cr239.00 Cr43.00 Cr-813.68 Cr857.97 Cr1,007.05 Cr1,365.85 Cr
Tax Provision -3.70 Cr-8.16 Cr71.76 Cr-18.24 Cr-113.30 Cr148.18 Cr98.90 Cr-180.70 Cr212.75 Cr197.66 Cr301.66 Cr
Net Income -130.00 Cr42.00 Cr479.00 Cr-934.00 Cr-224.00 Cr91.00 Cr-56.00 Cr-588.73 Cr598.88 Cr774.22 Cr1,041.77 Cr
Diluted EPS -3.100.408.14-19.46-3.960.77-1.457.357.807.9310.2613.80

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 7,592.00 Cr7,232.00 Cr9,588.00 Cr8,479.00 Cr11,486.00 Cr11,036.00 Cr10,866.00 Cr-12,433.60 Cr13,288.78 Cr13,691.53 Cr15,966.23 Cr
Current Assets --------1,406.35 Cr1,420.59 Cr1,471.36 Cr1,819.42 Cr
Cash & Equivalents --------141.08 Cr235.27 Cr139.72 Cr406.97 Cr
Inventory --------122.84 Cr107.42 Cr115.29 Cr135.27 Cr
Receivables --------510.08 Cr555.81 Cr711.45 Cr938.56 Cr
Total Liabilities --------4,333.22 Cr4,732.64 Cr4,522.14 Cr5,797.72 Cr
Current Liabilities --------1,425.88 Cr3,170.17 Cr1,607.31 Cr2,115.00 Cr
Long Term Debt --------572.22 Cr740.85 Cr2,085.72 Cr2,401.16 Cr
Total Debt 1,784.00 Cr1,513.00 Cr2,217.00 Cr1,962.00 Cr2,010.00 Cr1,594.00 Cr1,531.00 Cr-925.72 Cr1,155.02 Cr2,475.11 Cr3,472.58 Cr
Total Equity 4,048.00 Cr4,461.00 Cr5,144.00 Cr4,062.00 Cr6,601.00 Cr6,661.00 Cr6,120.00 Cr-7,242.26 Cr7,662.90 Cr8,916.52 Cr9,895.55 Cr
Shares Outstanding --------75.50 Cr75.50 Cr75.50 Cr75.50 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 24.00 Cr195.00 Cr966.00 Cr493.00 Cr-179.00 Cr172.00 Cr485.00 Cr-822.25 Cr1,100.10 Cr1,423.93 Cr1,601.45 Cr
Investing Cash Flow 213.00 Cr122.00 Cr-1,001.00 Cr-333.00 Cr-3,279.00 Cr63.00 Cr-131.00 Cr--373.70 Cr-886.37 Cr-779.38 Cr-1,538.40 Cr
Financing Cash Flow -304.00 Cr-354.00 Cr259.00 Cr-672.00 Cr4,257.00 Cr-862.00 Cr-143.00 Cr--471.22 Cr-86.46 Cr-713.85 Cr163.76 Cr
Capital Expenditure -205.00 Cr-357.00 Cr-277.00 Cr-56.00 Cr-82.00 Cr-137.00 Cr-211.00 Cr--447.24 Cr-942.47 Cr-846.94 Cr-945.44 Cr
Free Cash Flow -181.00 Cr-162.00 Cr689.00 Cr437.00 Cr-261.00 Cr35.00 Cr274.00 Cr-375.01 Cr157.63 Cr576.99 Cr656.00 Cr
Net Change in Cash -66.00 Cr-37.00 Cr225.00 Cr-513.00 Cr799.00 Cr-627.00 Cr212.00 Cr--22.67 Cr127.27 Cr-69.30 Cr226.81 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------35.7%35.8%59.7%61.1%
Operating Margin % -3.2%-3.2%2.9%0.8%-0.0%6.9%2.8%-12.4%13.3%15.4%17.8%
Net Margin % -3.3%1.0%10.5%-20.5%-5.0%2.0%-1.4%-9.5%8.8%10.0%11.5%
ROE % -3.2%0.9%9.3%-23.0%-3.4%1.4%-0.9%-8.1%7.8%8.7%10.5%
ROCE % --------7.0%9.0%9.9%11.7%

Shareholding Pattern

Insiders
35.19%
Institutions
50.91%
Public Float
78.55%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FORTIS

Google News Fri, 04 Sep 2026

Fortis Inc. stock falls Friday, still outperforms market - MarketWatch

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNRHVVYXBBbFZRZlN4VzM2S211c0V4amRUWUg3Zm5sSHYxZENxS2xVcE4yLXJBbFJjdmRtdGVNd2lnRFJBS2NKZ1Z5N3ZscW1PZ3RmeW1Rb0RfbVVQVDJSVE9wejVZV3YzNU0wZG9GUnVIcy1MVFhWZ0tkSlRQODRvM2FsdlNRTk50Ylk2MX…

Google News Sun, 06 Sep 2026

2 TSX Dividend Stocks Retirees Can Buy and Hold for the Next Decade - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNZGEzNUVyeERuSDFreDlOTVlCNkROUFVxdzlrLVBxRlF3ZlBrT01JcW12aEl2V2Ztb1oxSWgzNXVaRmljZVN6eFEtbGRSRW5XZkdBdDFfUW5nZXB6OTMxZ3VSazBDN3BWZlBQM1FtX1M5NXBURWNub0plUU5JanY3cVFFYk5ZUQ?oc=5" t…

Google News Sun, 06 Sep 2026

BNP Paribas Fortis (ENXTBR:017250539) Stock Trails Revenue Strength As Margins Tighten - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQdmJpaVdzOVQzZW1NbkRLY25fMnFQSUE5RXpMRDh3OENaWW8tTkNBSFYyNVQzR1JoV0lxc0RHdC11TGpzVVpFQS0xbnl6LWUxc1U3S1J6Yml5LThNMnFhMUZUbkFJX1BCMkNtNk1iQW5ETFVTbzZkWU5VeUhqeTFQZVJSSzZiY3ppTXJ3bm…

Google News hu, 03 Sep 2026

Fortis Stock Slips 0.25% as Interest-Rate Sensitivity and Capital Spending Concerns Offset Utility Stability - kalkine.ca

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQSl9Ga1ZoZlpSVDFFejc0a2JmNzV0ckJIb3lfZ1RJamIyeXNrUG9iUjVwLTgySFY2Znp4TGl5ZG40U1BtbUs2cWpzYkxuM29VNmdKdVZDWWxxcXk3VGo3OThnb2V2UlgwT05ONjVrSjE0b1FFNlBGS1BFMXZ1R1BPWi1jSEcteTliZ3k3MU…

Google News Mon, 07 Sep 2026

Why Utility Stocks Watchers Are Eyeing Fortis Inc (TSX:FTS)? - Kalkine Media

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQM21fV1c0LUJydnRIN080T2JVaG5KelJvb2l1MlFPOURUZE9jNjF0cVEzUXBXeHhUMElMRTl2M25PelFyVW1iVVZtU1VqaEtfQ1VhSUJiSlFwMjU4UVNYV0ZRZ0YyNVBha3RWSXNFSGdPcDVxUktOWG1IejBhZDFIbUVDYmdGakY5TldHWk…

Google News hu, 03 Sep 2026

Fortis Inc. stock rises Thursday, still underperforms market - MarketWatch

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxORTdEVGNoYlcwQVNHWHdnUTFVaUJCMEZ1dDdHSTFYS0V3MW9ocDEtWUloOGhUSEVrc3JJTmVTNHZicUxIS09sRlNzUm1yN3R1TWpDLTNjd0pVYWV4UWFGdTltNkpfVkFLMlBRSENTZ2JkcTJLWHRMMTRnS0dVYWZQQzhLLWVKVWxxamNBcz…

FORTIS — Frequently Asked Questions

What is the current share price of Fortis Healthcare Limited (FORTIS)?

As of 2026-09-08 04:53 IST, Fortis Healthcare Limited (FORTIS) trades at ₹905.00 on NSE. Its 52-week range is ₹787.91 to ₹1,096.74.

What is the market capitalisation of FORTIS?

Fortis Healthcare Limited (FORTIS) has a market capitalisation of ₹68,323.71 Cr on NSE.

What is the P/E ratio of FORTIS?

FORTIS trades at a trailing price-to-earnings (P/E) ratio of 65.58. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 7.29.

Does FORTIS pay a dividend?

Fortis Healthcare Limited (FORTIS) currently offers a dividend yield of 0.11%.

What is the return on equity (ROE) of FORTIS?

FORTIS has a return on equity (ROE) of 10.53%. Its return on capital employed (ROCE) is 11.90%.

Is FORTIS a good stock to buy?

This page provides a data-driven analysis of Fortis Healthcare Limited (FORTIS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space